Leading companies spent $1.4 billion upfront on licensing deals and embarked on vast R&D programs. Clinical setbacks mean ...

With much to cover, Democrats tackled Kennedy’s MAHA report; the firing of all members of the CDC’s ACIP committee; and much ...

In addition to cutting most of its staff, including two C-suite executives, Leap Therapeutics is winding down research and ...

Isaralgagene civaparvovec is a “potential best-in-class gene therapy for Fabry disease,” according to analysts at H.C.

Revolution Medicines projected its cash and equivalents of $2.1 billion would last into the second half of 2027. With new ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...

In combination with Roche’s PD-L1 blocker Tecentriq, zanzalintinib bested Bayer’s Stivarga. Exelixis is positioning the drug ...

Drug pricing, budget cuts, tariffs and other shifts under the Trump administration undermine the biopharma and healthcare ...

Speaking at BIO2025, rare disease leaders from Ultragenyx, Amylyx and Yale questioned the need for the new regulatory pathway ...

Curay, who stepped into the role as the agency’s top drug regulator in January, is departing in July, according to an email ...

Although the company withheld detailed findings from the study of treatment-resistant depression, analysts at Stifel called ...